Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. Its pipeline includes ATNM-400, an investigational radioconjugate targeting a novel antigen in solid tumors; Actimab-A, a CD33-targeted… From the company’s description.
Over the twelve months to Jun 30, 2026, Actinium Pharmaceuticals, Inc. reported revenue of $35.09M and net income of $11.31M. Its operating margin was 27.2%, and operations used $22.66M in cash. In fiscal 2025, it reported revenue of $0.09M and a net loss of $33.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Actinium Pharmaceuticals, Inc. does
In the company’s own words
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. Its pipeline includes ATNM-400, an investigational radioconjugate targeting a novel antigen in solid tumors; Actimab-A, a CD33-targeted therapy being developed for acute myeloid leukemia and myelodysplastic syndromes as well as in combination with checkpoint inhibitors for solid tumors; and the CD45-targeted conditioning agents Iomab-B for bone marrow transplantation and Iomab-ACT for cell and gene therapies. The company conducts clinical development and radiochemistry research, and is building manufacturing capabilities for actinium-225 radiopharmaceuticals; it has no reportable business segments described. Its programs are intended for cancer patients, including people with relapsed or refractory blood cancers and patients receiving transplants or cell therapies. In fiscal 2025, Actinium reported no commercial product revenue; its clinical programs have been evaluated in more than 500 patients across over 15 trials. Its website is https://www.actiniumpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1388320
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Actinium Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Actinium Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Actinium Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Actinium Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Actinium Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”